GenScript Biotech vs Synthego Corporation
GenScript holds the stronger position right now because its revenue and profit are growing fast while Synthego already went through a bankruptcy sale.
GenScript Biotech
Chinese gene-synthesis and biologics CDMO serving 200k+ customers worldwide
Synthego Corporation
Makes synthetic guide RNA and CRISPR editing kits for labs and biopharma
Dimension by dimension
| Dimension | GenScript Biotech | Synthego Corporation |
|---|---|---|
| Staying power of the core product | GenScript's gene synthesis and biologics work grew group revenue 61.4% and its Life Science unit grew 14.8% in the same year. | Synthego's guide RNA and GMP reagent business shrank from 300 to 172 employees and was sold through a credit bid after bankruptcy. |
| Exposure to AI absorbing the product | AI is unlikely to replace the physical work of gene synthesis and biologics manufacturing. | AI is unlikely to replace the physical work of making guide RNA and GMP reagents. |
| How easily a giant could copy them | Large Western suppliers could plausibly replicate GenScript's synthesis and CDMO services too. | Thermo Fisher, Danaher's IDT, Merck KGaA, and Agilent could plausibly replicate Synthego's offering. |
| Pressure from direct rivals | GenScript shows no visible customer defection to Twist, IDT, or Thermo Fisher, so as assessed July 2026 it faces lighter direct pressure than Synthego. | Synthego faces named competition from Thermo Fisher, IDT, Merck KGaA, Agilent, and GenScript itself, and its business was ultimately liquidated through a bankruptcy sale. |
| Policy and country risk | GenScript's main threat is US policy directed at Chinese biotech firms rather than competitor actions. | Synthego is US based and its listed threats are competitors, not government policy. |
| Financial footing | GenScript posted $959.5 million in FY2025 revenue and $230.3 million in adjusted net profit. | Synthego raised $450 to $472 million total but was ultimately acquired for about $85 million through a credit bid. |
Questions people ask
- Synthego vs GenScript which is more financially stable
- GenScript is more financially stable, posting $959.5 million in revenue and $230.3 million in profit for FY2025. Synthego went through bankruptcy and was acquired for about $85 million, far below the $450 to $472 million it had raised.
- Is Synthego still operating after its bankruptcy
- Synthego was acquired through a credit bid for about $85 million in mid-2025 and continues to operate at a smaller scale, with headcount dropping from 300 to 172 over five years. GenScript did not go through any similar restructuring.
- Does GenScript face US government restrictions like other Chinese biotech firms
- GenScript's listed pressure comes from US policy risk rather than competitors, unlike Synthego whose named threats are direct rivals such as Thermo Fisher and IDT. Neither digest states that restrictions have already been enacted against GenScript.
- Could a big company like Thermo Fisher replace Synthego or GenScript
- Both companies are marked as likely to be copied by a larger competitor. Synthego already competes directly with Thermo Fisher and IDT in guide RNA, while GenScript's synthesis and CDMO work could similarly be replicated by larger Western suppliers.